Boerner et al. «Production of Antigen - Specific
Human Monoclonal Antibodies From In Vitro - Primed Human Splenocytes», The Journal of Immunology, 147 (1): 86 - 95, 1991.
Researchers at Vanderbilt University Medical Center and the University of Texas Medical Branch in Galveston (UTMB) reported this week in the journal Cell that they have isolated
human monoclonal antibodies from Ebola survivors that can neutralize multiple species of the virus.
Not exact matches
Aflatoxin M1 in
human breast milk
from The Gambia, west Africa, quantified by combined
monoclonal antibody immunoaffinity chromatography HPLC.
Researchers report in Nature today that they have perfected a way to manufacture
monoclonal antibodies capable of destroying diseases such the avian flu, which have the ability to swap genes with
human flu varieties and jump
from birds to people.
To avoid these problems, researchers have been trying to perfect and speed up procedures for extracting
monoclonal antibodies from humans, replicating them in a lab, and then injecting them into victims suffering
from the diseases they were formed to fight.
In the current study, Vanderbilt researchers led by graduate student Andrew Flyak, the paper's first author, used a high - efficiency method they developed to quickly isolate and generate large quantities of
monoclonal human antibodies from the blood of survivors of a 2007 outbreak in Uganda who were infected by the Bundibugyo ebolavirus.
Thus, this study has implications for analysis of
human vaccine studies, as in addition to searching for defined lineages it is worthwhile to perform functional analysis of
monoclonal antibodies that may have found new structural solutions to high affinity binding which can not be discerned
from DNA sequence alone.
Immunoblot analysis using mouse
monoclonal antibody to
human IgM detected IgM to cytomegalovirus (CMV)- specific proteins (150, 42, 38, 32, and 28 kDa) in 74 (38 %) of 197 seropositive serum samples
from 197 individuals in three subject groups: 43 surgical patients, 31 patients with solid tumors, and 123 healthy individuals.
Fishwild et al. «High - Avidity
Human IgGK
Monoclonal Antibodies From A Novel Strain of Minilocus Transgenic Mice», Nature Biotechnology, 14: 845 - 851, 1996.
Some of the important and pioneering work for which Cambridge is best known and which has led to major improvements in people's lives was only possible using animals,
from the development of IVF techniques through to
human monoclonal antibodies.